Back
75· Active
Health & Science2h 19m ago
An independent panel of experts voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s drug, donanemab, outweigh its risks for patients in early stages of the disease.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) advisory committee
What
An independent panel of experts voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s drug, donanemab, outweigh its risks for patients in early stages of the disease.
When
Wed, 10 Jun 2026 06:10:05 GMT · 2h 19m ago
Where
Silver Spring, Maryland, USA · 39.0298°N, 76.9950°W
Why
The decision was based on Phase 3 trial data showing the drug significantly slowed cognitive and functional decline in patients with early symptomatic Alzheimer’s.
The Frontline Impact
How this affects you
This recommendation paves the way for a second major treatment option to slow the progression of Alzheimer’s, potentially offering millions of families more time with loved ones.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.